Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 21:10:25151355221084535.
doi: 10.1177/25151355221084535. eCollection 2022.

Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review

Catherina X Pan  1 , Michelle S Lee  1 , Vinod E Nambudiri  2
Affiliations
Review

Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review

Catherina X Pan et al. Ther Adv Vaccines Immunother. .

Abstract

Herpes zoster (HZ) is a neurocutaneous disease that causes significant morbidity worldwide. The disease is caused by the reactivation of the varicella-zoster virus (VZV), which leads to the development of a painful, vesicular rash and can cause complications such as post-herpetic neuralgia and vision loss. Globally, the incidence of HZ is increasing, and it incurs billions in cost annually to the healthcare system and to society through loss of productivity. With the advent of effective vaccines such as the live attenuated vaccine, Zostavax®, in 2006, and more recently the adjuvant recombinant subunit vaccine, Shingrix®, in 2017, HZ has become a preventable disease. However, access to the vaccines remains mostly limited to countries with developed economies, such as the United States and Canada. Even among countries with developed economies that license the vaccine, few have implemented HZ vaccination into their national immunization schedules due to cost-effectiveness considerations. In this review, we discuss the currently available HZ vaccines, landscape of HZ vaccine guidelines, and economic burden of disease in countries with developed and developing economies, as well as barriers and considerations in HZ vaccine access on a global scale.

Keywords: access; developed countries; developing countries; herpes zoster; shingles; vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Herpes zoster vaccines SAGE Working Group on Varicella and Herpes Zoster Vaccines, https://www.who.int/immunization/sage/meetings/2014/april/2_Background_d... (2014, accessed 17 October 2021).
    1. Keating GM. Shingles (Herpes Zoster) vaccine (Zostavax®): a review in the prevention of herpes zoster and postherpetic neuralgia. Biodrugs 2016; 30: 243–254. - PubMed
    1. Gagliardi AMZ, Andriolo BNG, Torloni MR, et al.. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev 2019; 2019: CD008858. - PMC - PubMed
    1. Johnson RW, Alvarez-Pasquin M-J, Bijl M, et al.. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines 2015; 3: 109–120. - PMC - PubMed
    1. Harvey M, Prosser LA, Rose AM, et al.. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition. Pain 2020; 161: 361–368. - PubMed

LinkOut - more resources